Corgenix Medical Corp. (fka CONX)

[Hegotgame]

CONX...Corgenix Medical Corporation Announces New AtherOx(R) (Oxidized LDL
Technology) License and Cooperation Agreement
Previously disclosed arbitration
demand rescinded


DENVER, Sep 10, 2013 (BUSINESS WIRE) -- Corgenix Medical Corporation (OTCQB:
CONX.OB), a worldwide developer and marketer of diagnostic test kits, today
announced signing of a new AtherOx(R) License and Cooperation
Agreement with Eiji Matsuura, Ph.D., an individual of Okayama, Japan.
Concurrently with the execution of the new agreement, Dr. Matsuura terminated
his arbitration demand of June 28, 2013 related to the April 14, 2010 Amended
and Restated License Agreement between the parties.

The New Agreement grants a worldwide license to Corgenix, to utilize the
AtherOx(R) technology to exclusively develop and manufacture, and
co-exclusively sell diagnostic products during the term of the Agreement, which
expires in 2022. In Japan, Corgenix will have the exclusive rights to utilize
the AtherOx(R) technology to develop, manufacture and use, but
not to sell the related AtherOx(R) products other than at the
direction of Dr. Matsuura. Pursuant to the new Agreement, Corgenix will have to
achieve certain specified milestones at each of the three anniversaries after
the effective date (September 3, 2013).

Previous clinical data presented at several scientific and medical meetings
demonstrated a significant correlation between serum levels of the patented
AtherOx(R) bio-markers and cardiovascular disease. Luis Lopez,
MD, Corgenix' Medical Director, said
"Interestingly, data from the studies suggests that
AtherOx alone or when combined with anti-phospholipid antibodies predict an
increased risk for vascular complications in coronary artery disease patients.
In addition, the findings indicate important relationships between
AtherOx(R) and the severity of cardiovascular
disease."

Commenting on today's announcement, Douglass Simpson,
President and CEO of Corgenix, stated, "We are
extremely excited to renew and expand our relationship with Dr. Matsuura and
retain the rights to the AtherOx(R) technology. We believe this
unique science targets a significant worldwide clinical need, and we look
forward to seeing additional data over the next few years, leading to the
opportunity to bring these products to the market. As new clinical findings
continue to validate the utility of AtherOx(R), we anticipate
that this technology has the potential to become an important addition to
medical care worldwide."

About AtherOx(R)

Corgenix originally licensed the proprietary AtherOx(R)
technology in 2002 from Dr. Matsuura. During the ensuing years, Corgenix has
incorporated this technology into products, conducting multiple studies that
further validate the impressive preclinical data generated by Professor
Matsuura. The AtherOx(R) technology utilizes oxidized
low-density-lipoprotein (oxLDL) complexed with the plasma protein B2GPI (Ox
LDL/B2GPI). Although oxLDL has been implicated in atherosclerotic cardiovascular
disease, clinical data suggests that the determination of AtherOx, rather than
oxLDL alone, is more predictive of the risk of progressive atherosclerotic
cardiovascular disease. Four U.S. patents have been issued and several others
are pending.

Products using the AtherOx(R) technology have not been cleared by
the U.S. Food and Drug Administration for in vitro diagnostic use in the United
States. In all countries where the use of this product has not been cleared by
local regulating agencies, products using this technology shall not be used for
diagnostic use as the performance characteristics have not been established.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized
diagnostic kits for immunology disorders, vascular diseases and bone and joint
disorders, including the world's only non-blood-based
test for aspirin effect. Corgenix diagnostic products are commercialized for use
in clinical laboratories throughout the world. The company currently sells over
50 diagnostic products through a global distribution network and has significant
experience in product submissions to the FDA and other worldwide regulatory
authorities. Additionally, Corgenix contract develops and manufactures products
for key medical and life science companies in state-of-the-art facilities in
Colorado. The company operates under a Quality Management System that is ISO
13485:2012 certified and compliant with FDA regulations. More information is
available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are
"forward-looking"
statements (identified by the words
"believe",
"estimate",
"project",
"expect" or similar
expressions) within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements, which are inherently uncertain, are based on
management's current expectations and are subject to
various factors, risks and uncertainties that may cause actual results, outcome
of events, timing and performance to differ materially from those expressed or
implied by such forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, continued
acceptance of the Company's products and services in
the marketplace, competitive factors, changes in the regulatory environment, and
other risks detailed in the Company's periodic
reports filed with the Securities and Exchange Commission, and in the
Company's subsequent filings with the Securities and
Exchange Commission. The statements in this press release are made as of today,
based upon information currently known to management, and the Company does not
undertake any obligation or intend to publicly update or revise any
forward-looking statements.


http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130910005383r1&sid=cmtx6&distro=nx

SOURCE: Corgenix Medical Corp.




CONTACT:
Corgenix Medical Corp.
Company Contact:
William Critchfield, 303-453-8903
Senior VP and CFO
[e-mail]
or
Media Contact:
Armada Medical Marketing
Dan Snyders, 303-623-1190 x 230
Vice President and Public Relations Supervisor
[e-mail]




Copyright Business Wire 2013

-0-




KEYWORD: United States

Japan

Asia Pacific

North America

Colorado

INDUSTRY KEYWORD: Health

Biotechnology

Cardiology

Clinical Trials

Genetics

Medical Devices

SUBJECT CODE: Contract/Agreement